The estimated Net Worth of Jerome Groopman is at least $10 Tausend dollars as of 19 May 2020. Jerome Groopman owns over 10,000 units of Onconova Therapeutics Inc stock worth over $10,001 and over the last 11 years he sold ONTX stock worth over $0. In addition, he makes $0 as Director at Onconova Therapeutics Inc.
Jerome has made over 2 trades of the Onconova Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ONTX stock worth $3,600 on 19 May 2020.
The largest trade he's ever made was buying 10,000 units of Onconova Therapeutics Inc stock on 19 May 2020 worth over $3,600. On average, Jerome trades about 715 units every 101 days since 2013. As of 19 May 2020 he still owns at least 10,001 units of Onconova Therapeutics Inc stock.
You can see the complete history of Jerome Groopman stock trades at the bottom of the page.
Dr. Jerome E. Groopman, M.D. has been appointed as Director of Onconova Therapeutics, Inc., effective July 25, 2013. Dr. Groopman has served as the Dina and Raphael Recanati Professor of Medicine at Harvard Medical School since January 1992. He has also served as Attending Hematologist/Oncologist at Beth Israel Deaconess Medical Center since July 1996. Dr. Groopman received an M.D. from Columbia University College of Physicians and Surgeons, and a B.A. in Political Philosophy from Columbia College.
Jerome Groopman is 64, he's been the Director of Onconova Therapeutics Inc since 2013. There are 7 older and 4 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Jerome's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 und Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: